DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation

Mikeska, Thomas; Bock, Christoph; Do, Hongdo; Dobrovic, Alexander

doi:10.1586/erm.12.45

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation

MPG-Autoren

/persons/resource/persons44148

Bock, Christoph
Computational Biology and Applied Algorithmics, MPI for Informatics, Max Planck Society;

Externe Ressourcen

Es sind keine externen Ressourcen hinterlegt

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Es sind keine frei zugänglichen Volltexte in PuRe verfügbar

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Mikeska, T., Bock, C., Do, H., & Dobrovic, A. (2012). DNA Methylation Biomarkers in Cancer: Progress Towards Clinical Implementation. Expert Review of Molecular Diagnostics, 12(5), 473-487. doi:10.1586/erm.12.45.

Zitierlink: https://hdl.handle.net/11858/00-001M-0000-0014-C824-4

Zusammenfassung

Altered DNA methylation is ubiquitous in human cancers and specific methylation changes are often correlated with clinical features. DNA methylation biomarkers, which use those specific methylation changes, provide a range of opportunities for early detection, diagnosis, prognosis, therapeutic stratification and post-therapeutic monitoring. Here we review current approaches to developing and applying DNA methylation biomarkers in cancer therapy. We discuss the obstacles that have so far limited the routine use of DNA methylation biomarkers in clinical settings and describe ways in which these obstacles can be overcome. Finally, we summarize the current state of clinical implementation for some of the most widely studied and well-validated DNA methylation biomarkers, including SEPT9, VIM, SHOX2, PITX2 and MGMT.